Abstract. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer 2008;18: Pathology REVIEW PAPER
|
|
- Hilary Wood
- 7 years ago
- Views:
Transcription
1 Int J Gynecol Cancer 2008, 18, REVIEW PAPER Mucinous ovarian cancer M.L. HARRISON*, C. JAMESONy & M.E. GORE* Departments of *Medicine and yhistopathology, Royal Marsden Hospital, London, United Kingdom Abstract. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer 2008;18: Mucinous epithelial ovarian cancer (meoc) accounts for approximately 10% of EOCs. Patients presenting with early-stage disease have an excellent prognosis, however, those with advanced disease have a poor outcome with relative resistance to standard ovarian cancer chemotherapy. Molecular and genetic studies demonstrate differences between mucinous and serous EOC supporting the concept that these tumors develop along separate pathways. Together with the observed differences in clinical behavior and outcome for meoc, there is a need to develop specific therapeutic strategies for this histologic subtype. The relative rarity of advanced meoc has resulted in few patients enrolled in major ovarian cancer trials. The results of such trials may not necessarily reflect those specific to meoc. Separate trials testing alternative chemotherapeutics are required. Metastatic mucinous tumors from other sites such as the gastrointestinal tract may present with ovarian involvement. For all mucinous tumors of the ovary, establishing primary as opposed to metastatic cancers is important. Clinical presentation, tumor markers, histologic, and immunohistochemical features are helpful in distinguishing most cases. KEYWORDS: chemotherapy, epithelial ovarian cancer, molecular studies, mucinous, pathology. Address correspondence and reprint requests to: Martin E. Gore, PhD, FRCP, Department of Medicine, Royal Marsden Hospital, Fulham Road, LondonSW36JJ, UK. martin.gore@rmh.nhs.uk doi: /j x Invasive mucinous carcinoma of the ovary accounts for approximately 10% of epithelial ovarian cancers (EOC) (1). Despite the infrequency of this subtype, 27% of patients with stage I EOC have mucinous pathology as opposed to less than 10% of patients presenting with stage III/IV tumors (2,3). They appear to have a different natural history from the other histologic types in terms of presentation, response to therapy, and outcome. In an analysis of prognostic factors for FIGO stage I invasive ovarian cancers, 410 patients with mucinous epithelial ovarian cancer (meoc) were included and the 5-year disease-free survival was 90.8%. The hazard ratio for recurrence was 0.37 (95% CI, ) for meoc compared to other histologic types. Mucinous pathology was not a significant prognostic factor on multivariate analysis, with degree of differentiation as the most important independent prognostic variable (2). Most meoc are either well or moderately differentiated and this contributes to the low risk of relapse for FIGO stage I tumors. In contrast, patients with advanced meoc have a poor response to chemotherapy with relative resistance to platinum-based therapy, and an inferior outcome is well recognized. Case-control studies have highlighted differences in response and survival for meoc compared to other histologic types for standard therapies. Furthermore, molecular studies support the hypothesis that meoc should be considered as a biologically distinct entity. Tumors with mucinous pathology are underrepresented in randomized clinical trials of first-line chemotherapy in advanced disease, and usually account for less than 5% of all patients. Furthermore, in studies of second- and third-line chemotherapy, the percentage of patients with meoc is often not specified. These trials tend to mainly include patients with serous and endometrioid tumors and, therefore, the results are not generally applicable to patients with mucinous tumors. However, in the absence of alternative data to guide management, standard treatment of ovarian cancer with debulking surgery and platinum-based chemotherapy is given to patients with meoc. Pathology Mucinous tumors of the ovary are categorized according to the World Health Organization classification. # 2007, Copyright the Authors Journal compilation # 2007, IGCS and ESGO
2 210 M.L. Harrison et al. They include cystadenomas, borderline tumors (intestinal and endocervical types), noninvasive (intraglandular and intraepithelial) carcinomas, invasive carcinomas, and metastatic from other sites. Mucinous tumors are often heterogeneous in composition and thorough pathologic examination with extensive sampling is required. It is recommended that at a minimum, one block per centimeter of tumor is sampled. Invasive mucinous carcinomas commonly have an expansive growth pattern, are usually stage I at diagnosis, and have an excellent prognosis. An infiltrative growth pattern is less frequent but appears to follow a more aggressive course, accounting for most of the cases of advanced-stage mucinous tumors (4 6). Nuclear grade has been identified as an adverse prognostic feature. For stage I mucinous tumors, one study found tumor grade to be an independent predictive factor for relapse (6), although this has not been found consistently (4,5). It should be acknowledged that numbers in these retrospective studies are limited and follow-up data are not always complete. DNA ploidy, which looks at the DNA content of a cell, has been identified as a prognostic marker of survival in EOC (7), however, there is little data on this specific for invasive mucinous tumors (8). Within mucinous tumors mural nodules may be appreciated, and these are distinct from the underlying tumor. There are conflicting reports on the prognostic importance of nodules of anaplastic carcinoma (6,9). These nodules may occur in either borderline or invasive mucinous tumors and may not be an adverse feature in stage IA tumors (6). Their presence should not influence the management of earlystaged tumors. Mucinous tumors arising in the ovary need to be distinguished from metastatic ovarian involvement from other primary sites. These are most commonly from the lower gastrointestinal tract and appendix but may also arise from the stomach, small bowel, pancreas, biliary tree, cervix, endometrium, and breast. The primary may not be apparent at diagnosis (10 12). There are several features that may suggest a nonovarian primary including preoperative tumor markers, size of the ovarian tumor, and whether there is unilateral or bilateral ovarian involvement. Light microscopy findings and immunohistochemistry profile may help to distinguish between primary and metastatic disease, although diagnostic uncertainty may remain. Primary meoc are typically larger and more frequently unilateral than metastatic mucinous adenocarcinomas. In comparative studies, the mean size of meoc was cm (range 5 48 cm) and for metastatic involvement cm (range 2 24 cm). Size alone is not sufficient to distinguish between the two clinical scenarios, as 32 48% of metastatic tumors were found to be greater than 10 cm. Bilateral tumors were found in 0 17% of cases for meoc compared to 75 77% of cases for metastatic involvement (10 12). Seidman et al. proposed an algorithm incorporating these two factors and used a cutoff of greater or less than 10 cm. Based on tumor size being greater than 10 cm and unilateral involvement, meoc was correctly predicted in 82% of cases. For tumor size less than 10 cm and bilateral involvement, metastatic mucinous adenocarcinoma was correctly predicted in 95% of cases (10). Others have suggested that for unilateral tumors, tumor size greater than 15 cm may be more accurate. In a retrospective sample of patients with unilateral tumors greater than 10 cm, a primary ovarian tumor was diagnosed in 50% and 69% for size cm and greater than 15 cm, respectively (11). Histologic features are helpful in differentiating primary and metastatic mucinous adenocarcinomas of the ovary. Primary meoc is more likely to have an expansile pattern of invasion, complex papillary pattern, microscopic cysts, and necrotic luminal debris. The presence of a coexisting ovarian lesion supports the diagnosis of a primary ovarian tumor, although it should be noted that these deceptively benign appearances may be seen in tumors metastatic to the ovary. Factors supportive of metastatic involvement include nodular growth pattern, ovarian surface involvement by epithelial cells (surface implants), an infiltrative invasive pattern, single cell infiltration, hilar involvement, and signet ring cells (12). These histologic features may be helpful, however, they are not specific and intraobserver variability exists. The presence of so-called dirty necrosis and segmental necrosis of tumoral glands are characteristic for metastatic colorectal carcinoma and suggest this diagnosis when present. Immunohistochemistry may assist in distinguishing the primary site, and cytokeratin (CK) stains are routinely used. An immunoprofile of CK 7 positive/ck 20 negative favor a primary ovarian tumor, while CK 7 negative/ck 20 positive suggest metastatic involvement (Figs. 1 and 2). Primary mucinous ovarian tumors can stain positively for CK 20, although this is usually weak and focal. Likewise colorectal tumors, which typically are strongly CK 20 positive, may be negative particularly in right-sided or poorly differentiated tumors. Mucinous tumors from the appendix and upper gastrointestinal tract may stain CK 7 positive. We can therefore not rely on the CK 7/CK 20 immunoprofile alone. Other immunohistochemical markers may be helpful (13 18) (Table 1).
3 Invasive mucinous carcinoma of the ovary 211 Table 1. Differentiating meoc, seoc, and gastrointestinal tumors using serum tumor markers, immunohistochemistry, and molecular markers Tumor meoc seoc Colorectal Appendix Stomach Pancreas Immunohistochemistry CK /1 1 1 CK20 1/ /2 1 CA125 2/ CEA 1 2/ ER/PR WT Molecular markers p k-ras Tumor markers CA 125 a 2/1 1 2/1 2/1 2/1 2/1 CEA 1/2 2/1 1 1/2 2/1 2/1 CA19.9 2/1 2/1 1/2 1/2 2/1 1 CA125, carbohydrate antigen 125; ER/PR, estrogen receptor/ progesterone receptor; WT1, Wilms tumor gene product; CA19.9, carbohydrate antigen 19.9; 1, usually positive; 2, usually negative; 1/2, often positive; 2/1, often negative. a Often a marker of peritoneal dissemination. Figure 1. Primary mucinous adenocarcinoma of ovary. Note the abundant mucin production. This tumor stained positively for CK7 and was negative for CK20. Molecular studies Molecular differences in meoc and serous epithelial ovarian cancer (seoc) have been observed suggesting that these tumors should be regarded as separate entities. These studies have identified overexpression of the k-ras oncogene and a relative absence of mutations of the tumor suppressor gene p53 for meoc in contrast to seoc where the converse is seen (19,20). Interestingly, mucinous tumors of gastrointestinal origin, such as colorectal and pancreatic cancers, are also known to have overexpression of the k-ras oncogene (21,22). There is data supporting the development of meoc through an adenoma carcinoma sequence originating from cystadenomas and mucinous borderline tumors. Normal epithelium and sites of transitional epithelium may be seen adjacent to borderline or invasive mucinous tumors (23). Mutations in k-ras are likely to represent an early genetic lesion in the development of meoc. Increasing frequency of k-ras mutations in benign, borderline, and malignant mucinous tumors have been demonstrated (24), and similar k-ras mutations in adjacent benign and borderline areas of grade 1 mucinous adenocarcinomas have been observed (25). Gene expression profiling of mucinous tumors demonstrate a hierarchical clustering relationship between grade 1 mucinous adenocarcinomas and borderline tumors, which is distinct from cystadenomas and normal ovarian surface epithelium. Binary tree analysis showed that there are a number of co-regulated genes Table 2. Response to first-line platinum-based ovarian cancer chemotherapy Study n RR (%) PFS (mos) OS (mos) Hess et al., Pectasides et al., Pisano et al., NR NR RR, response rate; mos, months; NR, not reported. Figure 2. Secondary mucinous adenocarcinoma of the jejunum in the ovary. This tumor stained positively for CK20 and CEA. It was negative for CK7. Note the marked similarities in architecture between the two tumors histologically.
4 212 M.L. Harrison et al. shared between cystadenomas and other mucinous tumors (26). These data are consistent with the other molecular studies that have demonstrated a link among the various mucinous tumors and support the hypothesis that invasive tumors may evolve from their benign counterparts. Genetic abnormalities The majority of women with hereditary ovarian cancer have a germline mutation in either BRCA1 or BRCA2. Approximately 10% of women diagnosed with invasive EOC will carry a mutation in one of these genes. BRCA1 and BRCA2 ovarian cancers have predominantly serous pathology and present with advanced disease. meoc is not associated with these mutations, again illustrating that these tumors develop along separate pathways (27). Tumor markers The tumor marker profile at presentation, in particular the ratio of the serum CA125 and carcinoembryonic antigen (CEA) levels, has been identified as a useful diagnostic aid to identify patients who warrant investigation of the gastrointestinal tract preoperatively. A serum CA125/CEA ratio of greater than 25 has been found to have the highest discriminative value in distinguishing ovarian and colorectal primaries (28). Among the histologic types of EOC, case-control studies have shown that absolute values of CA125 at diagnosis were lower for patients with meoc compared with seoc (29,30). Additionally, CEA levels are frequently raised in the meoc (31) (Table 1). Therefore this model, which relates to the preoperative assessment using tumor markers to differentiate between an ovarian or gastrointestinal primary prior to a histologic diagnosis, is likely to be less discriminatory for meoc. Clinical studies Small retrospective studies have reported response rates of 26 42% to platinum-based first-line chemotherapy confirming platinum resistance for most mucinous ovarian tumors (29,30,32) (Table 2). In view of the rarity of this histologic subtype in patients with advanced disease, phase III trials of chemotherapy typically include too few patients with meoc to allow a meaningful analysis of the outcome for these patients. The International Collaborative Ovarian Neoplasm Group 1 and Adjuvant ChemoTherapy in Ovarian Neoplasms studies were performed in parallel and analyzed together. They investigated the role of adjuvant platinum-based chemotherapy in patients with stage I EOC, randomizing patients between immediate treatment and observation. There were 180 of 925 (19.5%) patients with meoc included in this trial and subgroup analysis for mucinous pathology did not find a statistically significant difference in outcome between adjuvant chemotherapy versus observation in this group. Thirty-three patients (18.3%) experienced disease relapse, which is greater than would be anticipated for stage I mucinous tumors. For patients with seoc, overall 20% relapsed (33). Less stringent surgical requirements with only one-sixth of patients being optimally surgically staged resulted in an unknown percentage with occult stage II or III disease. This may have affected the results and probably explains why there was an unusually high relapse rate for the patients with stage I meoc in this trial (33). The only large randomized clinical trial for advanced EOC which performed a separate analysis for meoc was the International Collaborative Ovarian Neoplasm 3 study. One hundred forty-eight of 2074 patients (7%) had mucinous pathology. They did not find a difference in progression-free survival (PFS) or overall survival (OS) for patients with mucinous pathology based on treatment received, carboplatin or carboplatin and paclitaxel. Their analysis was limited in that they did not report outcome for response rate, PFS or OS for patients with meoc compared to the other pathologic types. Therefore, based on this study, we cannot conclude whether patients with meoc have an inferior outcome compared with seoc to standard adjuvant chemotherapy (3). The Royal Marsden Hospital conducted a casecontrol study comparing the outcome of first-line platinum-based chemotherapy for advanced ovarian cancer for mucinous and nonmucinous pathology. Eighty-one patients were analyzed, 27 with mucinous pathology and 54 controls. The response rates were 26.3% (95% CI, %) versus 64.9% (95% CI, %) for mucinous pathology and controls, respectively (P ¼.01). Median PFS was 5.7 months (95% CI, months) versus 14.1 months (95% CI, months; P,.001) and OS was 12.0 months (95% CI, months) versus 36.7 months (95% CI, months; P,.001) for mucinous pathology and controls, respectively (29). The Hellenic Cooperative Oncology Group conducted a similar case-controlled study comparing first-line platinum-based chemotherapy on several study protocols for advanced ovarian cancer with mucinous and serous pathology. One hundred forty-one patients
5 Invasive mucinous carcinoma of the ovary 213 were analyzed, 47 with mucinous pathology and 94 with serous pathology. The response rates were 38.5% (95% CI, %) versus 70% (95% CI, %) for meoc and seoc, respectively (P ¼.001). Complete remission was 18% versus 47%. They did not find a significant difference in time to progression 11.8 months (95% CI, months) versus 20.0 months (95% CI, months) or OS 33.2 months (95% CI, months) versus 38.0 months (95% CI, months) for meoc and seoc, respectively, although there was a trend to a worse survival for patients with meoc (P ¼.46) (30). A retrospective study of 21 patients reviewed the response to first-line chemotherapy for patients with meoc; 19 patients had evaluable disease (12 with measurable disease and 7 assessed with second-look laparotomy). Eight (42%) patients with evaluable disease responded to first-line platinum-based chemotherapy (32). A small phase II trial enrolled 25 patients with platinum-refractory mucinous and clear cell ovarian cancer. Patients were treated with irinotecan and mitomycin C, and the authors reported a response rate of 52% (95% CI, %), with 5 (20%) complete responses (95% CI, %). The median OS was 15.3 months (34). Future directions There is a rationale for using the molecular and histopathologic characteristics of a tumor rather than its tissue of origin, as a basis for making treatment decisions. The latter consideration is well exemplified by the data on the behavior of advanced-stage meoc. At present, chemotherapy for all histologic subtypes of EOC is similar despite suggestions that there are real differences in response and outcome for patients with meoc and indeed other subtypes such as clear cell tumors. At present, there is an interest in investigating oxaliplatin in combination with either 5-fluorouracil or capecitabine. Oxaliplatin and 5-fluorouracil has been documented to have modest activity in platinum-resistant ovarian cancer (35,36). There has not been further exploration of irinotecan despite a promising response rate in combination with mitomycin C in this tumor type. Another potential strategy would include the addition of an anti-angiogenic agent such as bevacizumab. In addition to demonstrating single-agent activity in platinum-resistant ovarian cancer (37,38), bevacizumab has successfully been incorporated with chemotherapy in several tumor types, including colon cancer (39,40). The efficacy of these agents is yet to be established for meoc. There is an urgent need for prospective data from randomized studies to be generated and for such trials to have a translational component to better define the molecular characteristics and potential predictive factors for response in patients with meoc. References 1 McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002;84: Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357: International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either singleagent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360: Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas. A clinicopathologic study of 49 cases with long term follow-up. Am J Surg Pathol 1998;22: Lee K, Scully RE. Mucinous tumors of the ovary. A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with pseudomyxoma peritonei. Am J Surg Pathol 2000;24: Rodríguez IM, Prat J. Mucinous tumors of the ovary. A clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 2002;26: Kristensen GB, Kildal W, Abeler VM et al. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 2003;14: Guerrieri C, Hogberg T, Wingren S et al. Mucinous borderline and malignant tumours of the ovary. A clinicopathologic and DNA ploidy study of 92 cases. Cancer 1994;74: Prat J, Young RH, Scully RE. Ovarian mucinous tumors with foci of anaplastic carcinoma. Cancer 1982;50: Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003;27: Khunamornpong S, Suprasert P, Pojchamarnwiputh S et al. Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol 2006;101: Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 2003;27: Ji H, Isacson C, Seidman J et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002;21: Park SY, Kim HS, Hong EK et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002;33: Vang R, Gown AM, Barry TS et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 2006;30: Berezowski K, Stastny JK, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in colonic and ovarian carcinoma. Mod Pathol 1996;9: DeCostanzo DC, Elias JM, Chumas JC. Necrosis in 84 ovarian carcinomas: a morphologic study of primary versus metastatic colonic carcinoma with a selective immunohistochemical analysis of cytokeratin subtypes and carcinoembryonic antigen. Int J Gynecol Pathol 1997;16: Vang R, Gown AM, Barry TS et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006;19:
6 214 M.L. Harrison et al. 19 Pieretti M, Hopenhayn-Rich C, Khattar NH et al. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20: Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003;202: Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study. Br J Cancer 2001;85: Lohr M, Kloppel G, Maisonneuve P et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005;7: Puls LE, Powell DE, DePriest PD et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47: Cuatrecasas M, Villanueva A, Matias-Guiu X et al. K-ras mutations in mucinous ovarian tumors. A clinicopathologic and molecular study of 95 cases. Cancer 1997;79: Garrett AP, Lee KR, Colliti CR et al. k-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001; 20: Wamunyokoli FW, Bonome T, Lee J et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res 2006;12: Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68: Yedema C, Kenemans P, Wobbes T et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumour Biol 1992;13: Hess V, A Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004;22: Pectasides D, Fountzilas G, Aravantinos G et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2005;97: Tholander B, Taube A, Lindgren A et al. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol 1990;39: Pisano C, Greggi S, Tambaro R et al. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Anticancer Res 2005;25: Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95: Shimizu Y, Umezawa S, Hasumi K. A phase II study of combined CPT-11 and mitomycin-c in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singap 1998;27: Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin plus highdose leucovorin and 5-fluorouracil (FOLFOX 4) in platinumresistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 2004;95: Sundar S, Symonds RP, Decatris MP et al. Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol Oncol 2004;94: Burger RA, Sill M, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study [abstract]. Proc Am Soc Clin Oncol 2005;23:S16. Abstract Cannistra SA, Matulonis U, Penson R et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer [abstract]. Proc Am Soc Clin Oncol 2006;24:S18. Abstract Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. Proc Am Soc Clin Oncol 2005;23:S16. Abstract 2. Accepted for publication May 11, 2007
Ovarian mucinous lesions. Ovarian mucinous lesions: Common diagnostic dilemmas. Ovarian mucinous lesions: problematic issues
Ovarian mucinous lesions Ovarian mucinous lesions: Common diagnostic dilemmas Karuna Garg, MD University of California San Francisco Intestinal or usual type Seromucinous (Endocervical mucinous or Mullerian
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationPRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
More informationOutline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationCommon Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
More informationSentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationIntroduction to Pathology and Diagnostic Medicine
Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Introduction to Pathology and Diagnostic Medicine Spring 2003 What is pathology?
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationNational Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28)
National Coverage Determination (NCD) for Tumor Antigen by Immunoassay - CA 125 (190.28) Tracking Information Publication Number Manual Section Number 100-3 190.28 Manual Section Title Tumor Antigen by
More informationPractical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationToday s Topics. Tumors of the Peritoneum in Women
Today s Topics Tumors of the Peritoneum in Women Charles Zaloudek, M.D. Department of Pathology 505 Parnassus Ave., M563 University of California, San Francisco San Francisco, CA USA charles.zaloudek@ucsf.edu
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationFrequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationUnderstanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org
Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS foundationforwomenscancer.org Contents Introduction...1 CA 125................................... 1 The CA 125 Test...2 The Use of the CA
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationOptimal treatment of early-stage ovarian cancer
Annals of Oncology Advance Access published March 14, 2014 1 Optimal treatment of early-stage ovarian cancer F. Collinson *,1, W. Qian *,2, R. Fossati 3, A. Lissoni 4, C. Williams 5, M. Parmar 6, J. Ledermann
More informationMOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationThe Adnexal Mass and Early Ovarian Cancer
The Adnexal Mass and Early Ovarian Cancer Fred Ueland, MD University of Kentucky Gynecologic Oncology Never give in. Never give in. Never, never, never, never- in nothing great or small, large or petty-
More informationCorporate Medical Policy
Corporate Medical Policy Hyperthermic Intraperitoneal Chemotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hyperthermic_intraperitoneal_chemotherapy 5/19/2005 3/2016 3/2017
More informationFirst-line chemotherapy for the treatment of women with epithelial ovarian cancer
First-line chemotherapy for the treatment of women with epithelial ovarian cancer Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer June 2014
More informationSafe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer
Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer Camran Nezhat,, MD, FACOG, FACS Stanford University Medical Center Center for Special Minimally Invasive
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More informationCase of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
More informationChapter 9 SUMMARIZING DISCUSSION AND FUTURE PERSPECTIVES WELMOED REITSMA
Chapter 9 SUMMARIZING DISCUSSION AND FUTURE PERSPECTIVES WELMOED REITSMA 163 CHAPTER 9 SUMMARIZING DISCUSSION Epithelial ovarian cancer is the second most common gynecological malignancy and the deadliest
More informationCarbohydrate antigen 19 9 (CA 19 9) (serum, plasma)
Carbohydrate antigen 19 9 (CA 19 9) (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Carbohydrate antigen 19 9 (CA 19 9) 1.2 Alternative names Cancer antigen 19 9, cancer antigen GI
More informationImmunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationThe role of PARP inhibitors in high grade serous ovarian cancers
The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationSomething Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
More informationGenetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS -
Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS - January 2005 SCIENTIFIC BACKGROUND Breast cancer is considered to be one of the most prevalent cancer in women. The overall
More informationAbstract. Objectives. Methods. Results. a11111
RESEARCH ARTICLE Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients Shuang Ye 1, Jiaxin Yang 1, Yan
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationOvarian cancer. A guide for journalists on ovarian cancer and its treatment
Ovarian cancer A guide for journalists on ovarian cancer and its treatment Contents Contents 2 3 Section 1: Ovarian Cancer 4 i. Types of ovarian cancer 4 ii. Causes and risk factors 5 iii. Symptoms and
More informationLocoregional & advanced esophagus or esophagogastric junction cancer
Eloxatin (oxaliplatin) Prior Authorization Request (For Maryland Only) Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155 CVS/caremark administers the prescription
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationRenal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification Jesse K. McKenney, MD Associate Head, Surgical Pathology Renal Epithelial Neoplasia History 1981: WHO Classification of Renal Neoplasms 1.
More informationPATOLOGIA MOLECULAR DEL CANCER GINECOLOGICO. Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.
PATOLOGIA MOLECULAR DEL CANCER GINECOLOGICO Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA. Carcinoma de Endometrio Cáncer de Ovario Endometrial carcinoma
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationDevelopments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
More informationLuis D. Carcorze Soto, MD PGY-3
Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:
More informationPRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology
PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI
More informationSelecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer. Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK
Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK Overview of Presentation This presentation will discuss the management
More informationCytoreduction and hyperthermic intraperitoneal chemotherapy for the treatment of pseudomyxoma
Medical Policy Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pseudomyxoma Peritonei and Peritoneal Carcinomatosis of Gastrointestinal Origin, and Peritoneal Mesothelioma
More informationChirurgia Avanzata Del Carcinoma Ovarico Nuove Strategie A Confronto Ovarian Cancer Advanced Surgery New Strategies in Comparison
Peritoneal dissection and intraperitoneal chemotherapy under hyperthermic conditions. If you select the right patients long-term survival can be achieved. Chirurgia Avanzata Del Carcinoma Ovarico Nuove
More informationMolecular markers and clinical trial design parallels between oncology and rare diseases?
Molecular markers and clinical trial design parallels between oncology and rare diseases?, Harriet Sommer Institute for Medical Biometry and Statistics, University of Freiburg Medical Center 6. Forum Patientennahe
More informationThe Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.
Where does Molecular Analysis of FNA Specimens fit into the evaluation of thyroid nodules? The Role of Genetic Testing in the Evaluation of Thyroid Nodules Ultrasound TSH Risk factors Jill E. Langer, MD
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationWhat is neuroendocrine cervical cancer?
Key Points: 1. Neuroendocrine cancer of the uterine cervix is a rare and aggressive disease. 2. Treatment for neuroendocrine cervical cancer is usually more intensive than that for most other types of
More informationREVIEW ARTICLE. Key Words: CA 125, Ovarian cancer, Response, Progression, RECIST, Clinical trials
REVIEW ARTICLE Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) Gordon John Sampson Rustin,
More informationCOMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
More informationHereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013
Hereditary Ovarian cancer: BRCA1 and BRCA2 Karen H. Lu MD September 22, 2013 Outline Hereditary Breast and Ovarian Cancer (HBOC) BRCA1/2 genes How to identify What it means to you What it means to your
More informationBRAF in the diagnostic evaluation of thyroid nodules
Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF
More informationThe diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion
Malaysian J Path01 2002; 24(1) : 53-58 The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion Pavai STHANESHWAR MD, Sook-Fan YAP FRCPath, FRCPA and Gita JAYARAM MDPath, MRCPath
More informationMEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationPROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
More informationProtocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.
Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum. Protocol revision date: January 2004 No AJCC/UICC staging system
More informationEffusions: Mesothelioma and Metastatic Cancers
Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationCystic Neoplasms of the Pancreas: A multidisciplinary approach to the prevention and early detection of invasive pancreatic cancer.
This lecture is drawn from the continuing medical education program Finding Hope: Prevention, Early Detection and Treatment of Pancreatic Cancer, Nov, 2011. Robert P. Jury, MD Cystic Neoplasms of the Pancreas:
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationPancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
More informationOvarian Cancer Genetic Testing: Why, When, How?
Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationManagement of Platinum-Sensitive Recurrent Ovarian Cancer
Management of Platinum-Sensitive Jacobus Pfisterer a and Jonathan A. Ledermann b The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy.
More informationProtocol for the Examination of Specimens From Patients With Tumors of the Peritoneum
Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors and malignant mesothelial neoplasms of the
More information3 Summary of clinical applications and limitations of measurements
CA125 (serum) 1 Name and description of analyte 1.1 Name of analyte Cancer Antigen 125 (CA125) 1.2 Alternative names Mucin 16 1.3 NLMC code To follow 1.4 Description of analyte CA125 is an antigenic determinant
More informationFirst-line chemotherapy for women with epithelial ovarian cancer
First-line chemotherapy for women with epithelial ovarian cancer A systematic review July 2013 First line chemotherapy for women with epithelial ovarian cancer: a systematic review was prepared and produced
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationPOSTMENOPAUSAL ASSESS AND WHAT TO DO
POSTMENOPAUSAL OVARIAN CYSTS:HOW TO ASSESS AND WHAT TO DO Steven R. Goldstein, MD Professor of Obstetrics and Gynecology Director of Gynecologic Ultrasound Co-Director, Bone Densitometry New York University
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationPolyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1
Course AP104 Endometrial Hyperplasia A morphologic Definition Hyperplasias Hormonal Effect or Precancer? George L. Mutter, MD Harvard Medical School and Brigham and Women s Hospital Boston, MA Endometrial
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationVariations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes
JBUON 0; 8(): 608-6 ISSN: 07-065, online ISSN: 4-69 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Variations in tumor marker levels in metastatic breast cancer patients according to
More information